Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized pha
6 hours ago
- #nimotuzumab
- #chemoradiotherapy
- #nasopharyngeal carcinoma
- This randomized phase 2 trial tested adding nimotuzumab to concurrent chemoradiotherapy (CCRT) versus CCRT alone in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) who had a suboptimal response to induction chemotherapy.
- No significant improvement in 2-year progression-free survival was observed with nimotuzumab plus CCRT (81.0%) compared to CCRT alone (80.8%), with a hazard ratio of 0.93.
- Survival outcomes were similar between groups, and low-grade rash was more frequent with nimotuzumab, indicating the addition did not benefit this high-risk population and highlighting the need for predictive biomarkers and alternative strategies.